WILLIAM F DOYLE Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for WILLIAM F DOYLE.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of WILLIAM F DOYLE. WILLIAM F DOYLE is Director in OptiNose, Inc. ($OPTN) and Director in Minerva Neurosciences, Inc. ($NERV) and Director in Novocure Ltd ($NVCR) and Executive Chairman in Novocure Ltd ($NVCR).
Latest Insider Trading Transactions of WILLIAM F DOYLE
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, NERV, NVCR, OPTN
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 15 2021 | NERV | Minerva Neuroscien ... | DOYLE WILLIAM F | Director | Option Exercise | A | 2.90 | 40,000 | 116,000 | 40,000 | |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 216.69 | 600 | 130,016 | 555,393 | 556 K to 555.4 K (-0.11 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 214.67 | 500 | 107,333 | 555,993 | 556.5 K to 556 K (-0.09 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 213.35 | 1,500 | 320,021 | 556,493 | 558 K to 556.5 K (-0.27 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 211.28 | 600 | 126,766 | 557,993 | 558.6 K to 558 K (-0.11 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 210.18 | 521 | 109,504 | 558,593 | 559.1 K to 558.6 K (-0.09 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 209.34 | 2,200 | 460,555 | 559,114 | 561.3 K to 559.1 K (-0.39 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 207.80 | 4,500 | 935,118 | 561,314 | 565.8 K to 561.3 K (-0.80 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 206.35 | 1,284 | 264,956 | 565,814 | 567.1 K to 565.8 K (-0.23 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 205.43 | 1,600 | 328,690 | 567,098 | 568.7 K to 567.1 K (-0.28 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 204.28 | 1,972 | 402,834 | 568,698 | 570.7 K to 568.7 K (-0.35 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 203.25 | 2,555 | 519,311 | 570,670 | 573.2 K to 570.7 K (-0.45 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 202.16 | 4,388 | 887,069 | 573,225 | 577.6 K to 573.2 K (-0.76 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 201.55 | 4,125 | 831,377 | 577,613 | 581.7 K to 577.6 K (-0.71 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 199.71 | 4,338 | 866,355 | 581,738 | 586.1 K to 581.7 K (-0.74 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 198.98 | 10,563 | 2,101,794 | 586,076 | 596.6 K to 586.1 K (-1.77 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 197.83 | 13,612 | 2,692,876 | 596,639 | 610.3 K to 596.6 K (-2.23 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 197.00 | 24,338 | 4,794,659 | 610,251 | 634.6 K to 610.3 K (-3.84 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 196.07 | 8,814 | 1,728,187 | 634,589 | 643.4 K to 634.6 K (-1.37 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 194.94 | 1,600 | 311,904 | 643,403 | 645 K to 643.4 K (-0.25 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 193.57 | 2,090 | 404,563 | 645,003 | 647.1 K to 645 K (-0.32 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 192.52 | 1,900 | 365,796 | 647,093 | 649 K to 647.1 K (-0.29 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 191.26 | 1,400 | 267,768 | 648,993 | 650.4 K to 649 K (-0.22 %) |
| Aug 03 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 76.39 | 896 | 68,444 | 649,062 | 650 K to 649.1 K (-0.14 %) |
| Jun 12 2020 | NERV | Minerva Neuroscien ... | DOYLE WILLIAM F | Director | Option Exercise | A | 3.40 | 40,000 | 136,000 | 40,000 | |
| Jun 12 2020 | OPTN | OptiNose, Inc. | DOYLE WILLIAM F | Director | Option Exercise | A | 5.65 | 14,439 | 81,580 | 14,439 | |
| May 12 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 63.73 | 31,332 | 1,996,726 | 649,958 | 681.3 K to 650 K (-4.60 %) |
| May 11 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 0.00 | 58,767 | 0 | 0 | |
| May 11 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 0.00 | 58,768 | 0 | 58,767 | |
| May 11 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 63.50 | 31,903 | 2,025,872 | 681,290 | 713.2 K to 681.3 K (-4.47 %) |
| May 11 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 63.84 | 58,767 | 3,751,685 | 713,193 | 654.4 K to 713.2 K (+8.98 %) |
| May 11 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 64.74 | 30,993 | 2,006,518 | 654,426 | 685.4 K to 654.4 K (-4.52 %) |
| May 11 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 64.77 | 58,768 | 3,806,403 | 685,419 | 626.7 K to 685.4 K (+9.38 %) |
| May 07 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 0.00 | 58,768 | 0 | 117,535 | |
| May 07 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 0.00 | 58,768 | 0 | 117,535 | |
| May 07 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 0.00 | 58,768 | 0 | 176,303 | |
| May 07 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 0.00 | 58,768 | 0 | 176,303 | |
| May 07 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 64.15 | 58,768 | 3,769,967 | 626,651 | 567.9 K to 626.7 K (+10.35 %) |
| May 07 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 64.15 | 58,768 | 3,769,967 | 626,651 | 567.9 K to 626.7 K (+10.35 %) |
| May 07 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 64.27 | 29,881 | 1,920,452 | 567,883 | 597.8 K to 567.9 K (-5.00 %) |
| May 07 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 64.27 | 29,881 | 1,920,452 | 567,883 | 597.8 K to 567.9 K (-5.00 %) |
| May 07 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 62.47 | 30,283 | 1,891,718 | 597,764 | 628 K to 597.8 K (-4.82 %) |
| May 07 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 62.47 | 30,283 | 1,891,718 | 597,764 | 628 K to 597.8 K (-4.82 %) |
| May 07 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 61.40 | 58,768 | 3,608,355 | 628,047 | 569.3 K to 628 K (+10.32 %) |
| May 07 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 61.40 | 58,768 | 3,608,355 | 628,047 | 569.3 K to 628 K (+10.32 %) |
| May 06 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 0.00 | 58,768 | 0 | 235,071 | |
| May 06 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 60.48 | 58,768 | 3,554,289 | 569,279 | 510.5 K to 569.3 K (+11.51 %) |
| Mar 10 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 69.53 | 4,320 | 300,387 | 510,511 | 514.8 K to 510.5 K (-0.84 %) |
| Mar 02 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 0.00 | 9,259 | 0 | 9,259 | |
| Mar 02 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 72.22 | 3,893 | 281,133 | 514,831 | 518.7 K to 514.8 K (-0.75 %) |
| Mar 02 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 79.45 | 9,259 | 735,628 | 518,724 | 509.5 K to 518.7 K (+1.82 %) |
| Jan 22 2020 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 95.00 | 133,777 | 12,708,815 | 509,465 | 643.2 K to 509.5 K (-20.80 %) |
| Nov 26 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 96.04 | 16,223 | 1,558,057 | 643,242 | 659.5 K to 643.2 K (-2.46 %) |
| Nov 22 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 91.01 | 700 | 63,707 | 659,465 | 660.2 K to 659.5 K (-0.11 %) |
| Nov 22 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 90.36 | 149,300 | 13,490,016 | 660,165 | 809.5 K to 660.2 K (-18.44 %) |
| Nov 13 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 82.14 | 2,100 | 172,498 | 809,465 | 811.6 K to 809.5 K (-0.26 %) |
| Nov 13 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 81.59 | 11,118 | 907,118 | 811,565 | 822.7 K to 811.6 K (-1.35 %) |
| Nov 13 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 80.11 | 29,782 | 2,385,776 | 822,683 | 852.5 K to 822.7 K (-3.49 %) |
| Aug 01 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | A | 83.30 | 10,412 | 867,320 | 10,412 | |
| Aug 01 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Grant | A | 0.00 | 6,002 | 0 | 852,465 | 846.5 K to 852.5 K (+0.71 %) |
| Jul 01 2019 | NERV | Minerva Neuroscien ... | DOYLE WILLIAM F | Director | Buy | P | 5.50 | 3,500 | 19,250 | 26,111 | 22.6 K to 26.1 K (+15.48 %) |
| Jul 01 2019 | NERV | Minerva Neuroscien ... | DOYLE WILLIAM F | Director | Buy | P | 5.50 | 3,500 | 19,250 | 26,111 | 22.6 K to 26.1 K (+15.48 %) |
| Jun 13 2019 | NERV | Minerva Neuroscien ... | DOYLE WILLIAM F | Director | Option Exercise | A | 4.50 | 20,000 | 90,000 | 20,000 | |
| Jun 10 2019 | OPTN | OptiNose, Inc. | DOYLE WILLIAM F | Director | Option Exercise | A | 6.60 | 14,439 | 95,297 | 14,439 | |
| Jun 10 2019 | OPTN | OptiNose, Inc. | DOYLE WILLIAM F | Director | Option Exercise | A | 6.60 | 14,439 | 95,297 | 14,439 | |
| May 31 2019 | NERV | Minerva Neuroscien ... | DOYLE WILLIAM F | Director | Option Exercise | A | 5.21 | 20,000 | 104,200 | 20,000 | |
| May 31 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 53.10 | 1,900 | 100,881 | 894,563 | 896.5 K to 894.6 K (-0.21 %) |
| May 10 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | A | 47.56 | 35,000 | 1,664,600 | 35,000 | |
| May 10 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | A | 47.56 | 115,060 | 5,472,254 | 115,060 | |
| May 10 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 47.37 | 31,460 | 1,490,386 | 896,463 | 927.9 K to 896.5 K (-3.39 %) |
| May 09 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 0.00 | 58,768 | 0 | 293,839 | |
| May 09 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 0.00 | 58,768 | 0 | 352,607 | |
| May 09 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 47.62 | 58,768 | 2,798,532 | 927,923 | 869.2 K to 927.9 K (+6.76 %) |
| May 09 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 47.52 | 32,218 | 1,531,032 | 869,155 | 901.4 K to 869.2 K (-3.57 %) |
| May 09 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 48.92 | 58,768 | 2,874,931 | 901,373 | 842.6 K to 901.4 K (+6.97 %) |
| May 09 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 47.67 | 32,098 | 1,530,112 | 842,605 | 874.7 K to 842.6 K (-3.67 %) |
| May 07 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 0.00 | 58,768 | 0 | 411,375 | |
| May 07 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 48.89 | 58,768 | 2,873,168 | 874,703 | 815.9 K to 874.7 K (+7.20 %) |
| May 07 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 48.07 | 29,038 | 1,395,915 | 815,935 | 845 K to 815.9 K (-3.44 %) |
| May 06 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 0.00 | 58,768 | 0 | 470,143 | |
| May 06 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 0.00 | 58,768 | 0 | 528,911 | |
| May 06 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 44.60 | 58,768 | 2,621,053 | 844,973 | 786.2 K to 845 K (+7.47 %) |
| May 06 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 45.21 | 29,966 | 1,354,643 | 786,205 | 816.2 K to 786.2 K (-3.67 %) |
| May 06 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 43.28 | 58,768 | 2,543,479 | 816,171 | 757.4 K to 816.2 K (+7.76 %) |
| Mar 26 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | A | 47.04 | 44,953 | 2,114,589 | 44,953 | |
| Mar 26 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Grant | A | 0.00 | 24,554 | 0 | 942,860 | 918.3 K to 942.9 K (+2.67 %) |
| Mar 01 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 0.00 | 9,260 | 0 | 18,518 | |
| Mar 01 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 0.00 | 9,260 | 0 | 18,518 | |
| Mar 01 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 53.68 | 3,097 | 166,247 | 918,306 | 921.4 K to 918.3 K (-0.34 %) |
| Mar 01 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 53.68 | 3,097 | 166,247 | 918,306 | 921.4 K to 918.3 K (-0.34 %) |
| Mar 01 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 52.90 | 9,260 | 489,854 | 921,403 | 912.1 K to 921.4 K (+1.02 %) |
| Mar 01 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 52.90 | 9,260 | 489,854 | 921,403 | 912.1 K to 921.4 K (+1.02 %) |
| Dec 26 2018 | NERV | Minerva Neuroscien ... | DOYLE WILLIAM F | Director | Buy | P | 6.50 | 2,000 | 13,000 | 22,611 | 20.6 K to 22.6 K (+9.70 %) |
| Dec 26 2018 | NERV | Minerva Neuroscien ... | DOYLE WILLIAM F | Director | Buy | P | 6.50 | 2,000 | 13,000 | 22,611 | 20.6 K to 22.6 K (+9.70 %) |
| Dec 12 2018 | NERV | Minerva Neuroscien ... | DOYLE WILLIAM F | Director | Buy | P | 7.95 | 4,000 | 31,800 | 20,611 | 16.6 K to 20.6 K (+24.08 %) |
| Dec 12 2018 | NERV | Minerva Neuroscien ... | DOYLE WILLIAM F | Director | Buy | P | 8.00 | 2,000 | 16,000 | 16,611 | 14.6 K to 16.6 K (+13.69 %) |
| Nov 21 2018 | NERV | Minerva Neuroscien ... | DOYLE WILLIAM F | Director | Buy | P | 8.20 | 2,000 | 16,400 | 14,611 | 12.6 K to 14.6 K (+15.86 %) |
| Oct 15 2018 | NERV | Minerva Neuroscien ... | DOYLE WILLIAM F | Director | Buy | P | 10.00 | 600 | 6,000 | 12,611 | 12 K to 12.6 K (+5.00 %) |
| Sep 19 2018 | NERV | Minerva Neuroscien ... | DOYLE WILLIAM F | Director | Buy | P | 10.50 | 1,800 | 18,900 | 12,011 | 10.2 K to 12 K (+17.63 %) |
| Sep 19 2018 | NERV | Minerva Neuroscien ... | DOYLE WILLIAM F | Director | Buy | P | 10.50 | 1,800 | 18,900 | 12,011 | 10.2 K to 12 K (+17.63 %) |
| Sep 17 2018 | NERV | Minerva Neuroscien ... | DOYLE WILLIAM F | Director | Buy | P | 10.50 | 200 | 2,100 | 10,211 | 10 K to 10.2 K (+2.00 %) |
| Sep 17 2018 | NERV | Minerva Neuroscien ... | DOYLE WILLIAM F | Director | Buy | P | 10.50 | 2,000 | 21,000 | 10,011 | 8 K to 10 K (+24.97 %) |
| Sep 11 2018 | NERV | Minerva Neuroscien ... | DOYLE WILLIAM F | Director | Buy | P | 9.72 | 4,011 | 38,987 | 8,011 | 4 K to 8 K (+100.28 %) |
| Sep 11 2018 | NERV | Minerva Neuroscien ... | DOYLE WILLIAM F | Director | Buy | P | 9.88 | 4,000 | 39,520 | 4,000 | 0 to 4 K |
| Aug 20 2018 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | J | 0.00 | 187,787 | 0 | 438,167 | 626 K to 438.2 K (-30.00 %) |
| Aug 02 2018 | NERV | Minerva Neuroscien ... | DOYLE WILLIAM F | Director | Option Exercise | A | 7.95 | 20,000 | 159,000 | 20,000 | |
| Jul 18 2018 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 3.59 | 2,330 | 8,365 | 0 | |
| Jul 18 2018 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 3.59 | 2,330 | 8,365 | 914,473 | 912.1 K to 914.5 K (+0.26 %) |
| Jul 02 2018 | OPTN | OptiNose, Inc. | DOYLE WILLIAM F | Director | Option Exercise | J | 8.16 | 1,488,366 | 12,145,067 | 0 | |
| Jul 02 2018 | OPTN | OptiNose, Inc. | DOYLE WILLIAM F | Director | Sell | J | 0.00 | 2,195,914 | 0 | 817,225 | 3 M to 817.2 K (-72.88 %) |
| Jun 11 2018 | OPTN | OptiNose, Inc. | DOYLE WILLIAM F | Director | Option Exercise | A | 22.50 | 14,439 | 324,878 | 14,439 | |
| Jun 11 2018 | NERV | Minerva Neuroscien ... | DOYLE WILLIAM F | Director | Option Exercise | A | 8.25 | 20,000 | 165,000 | 20,000 | |
| May 10 2018 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Payment of Exercise | F | 28.26 | 28,652 | 809,620 | 912,143 | 940.8 K to 912.1 K (-3.05 %) |
| May 10 2018 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Payment of Exercise | F | 28.06 | 28,756 | 806,750 | 940,795 | 969.6 K to 940.8 K (-2.97 %) |
| May 08 2018 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Payment of Exercise | F | 28.01 | 28,804 | 806,771 | 969,551 | 998.4 K to 969.6 K (-2.89 %) |
| May 08 2018 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Payment of Exercise | F | 27.89 | 28,666 | 799,552 | 998,355 | 1 M to 998.4 K (-2.79 %) |
| May 04 2018 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 0.00 | 293,840 | 0 | 587,679 | |
| May 04 2018 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Payment of Exercise | F | 27.89 | 28,519 | 795,281 | 1,027,021 | 1.1 M to 1 M (-2.70 %) |
| May 04 2018 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 0.00 | 293,840 | 0 | 1,055,540 | 761.7 K to 1.1 M (+38.58 %) |
| Mar 01 2018 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | A | 0.00 | 27,778 | 0 | 27,778 | |
| Mar 01 2018 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | A | 21.15 | 202,758 | 4,288,332 | 202,758 | |
| Jan 24 2018 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 3.59 | 1,549 | 5,561 | 0 | |
| Jan 24 2018 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 3.59 | 1,549 | 5,561 | 92,746 | 91.2 K to 92.7 K (+1.70 %) |
| Dec 12 2017 | NERV | Minerva Neuroscien ... | DOYLE WILLIAM F | Director | Option Exercise | A | 5.70 | 40,000 | 228,000 | 40,000 | |
| Oct 19 2017 | OPTN | OptiNose, Inc. | DOYLE WILLIAM F | Director | Option Exercise | C | 0.00 | 92,543 | 0 | 0 | |
| Oct 19 2017 | OPTN | OptiNose, Inc. | DOYLE WILLIAM F | Director | Option Exercise | C | 0.00 | 190,440 | 0 | 0 | |
| Oct 19 2017 | OPTN | OptiNose, Inc. | DOYLE WILLIAM F | Director | Option Exercise | C | 0.00 | 41,160 | 0 | 0 | |
| Oct 19 2017 | OPTN | OptiNose, Inc. | DOYLE WILLIAM F | Director | Option Exercise | C | 0.00 | 719,225 | 0 | 0 | |
| Oct 19 2017 | OPTN | OptiNose, Inc. | DOYLE WILLIAM F | Director | Option Exercise | C | 0.00 | 334 | 0 | 0 | |
| Oct 19 2017 | OPTN | OptiNose, Inc. | DOYLE WILLIAM F | Director | Option Exercise | C | 0.00 | 473 | 0 | 0 | |
| Oct 19 2017 | OPTN | OptiNose, Inc. | DOYLE WILLIAM F | Director | Option Exercise | C | 0.00 | 1,142 | 0 | 0 | |
| Oct 19 2017 | OPTN | OptiNose, Inc. | DOYLE WILLIAM F | Director | Option Exercise | C | 0.00 | 4,563 | 0 | 0 | |
| Oct 19 2017 | OPTN | OptiNose, Inc. | DOYLE WILLIAM F | Director | Buy | C | 0.00 | 3,013,139 | 0 | 3,013,139 | 0 to 3 M |
| Oct 19 2017 | OPTN | OptiNose, Inc. | DOYLE WILLIAM F | Director | Buy | C | 0.00 | 18,803 | 0 | 18,803 | 0 to 18.8 K |
| Jun 15 2017 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Director | Option Exercise | M | 3.59 | 6,498 | 23,328 | 0 | |
| Jun 15 2017 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Director | Buy | M | 3.59 | 6,498 | 23,328 | 91,197 | 84.7 K to 91.2 K (+7.67 %) |
| May 04 2017 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | A | 0.00 | 881,519 | 0 | 881,519 | |
| May 04 2017 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | A | 11.85 | 881,519 | 10,446,000 | 881,519 | |
| May 04 2017 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | A | 11.85 | 881,519 | 10,446,000 | 881,519 | |
| Mar 09 2017 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | J | 0.00 | 19,732,767 | 0 | 43,000 | 19.8 M to 43 K (-99.78 %) |
| Mar 02 2017 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 3.59 | 525,618 | 1,886,969 | 0 | |
| Mar 02 2017 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | M | 3.59 | 686,836 | 2,465,741 | 0 | |
| Mar 02 2017 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Payment of Exercise | F | 7.60 | 248,285 | 1,886,966 | 19,775,767 | 20 M to 19.8 M (-1.24 %) |
| Mar 02 2017 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 3.59 | 525,618 | 1,886,969 | 20,024,052 | 19.5 M to 20 M (+2.70 %) |
| Mar 02 2017 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Payment of Exercise | F | 7.60 | 324,440 | 2,465,744 | 19,498,434 | 19.8 M to 19.5 M (-1.64 %) |
| Mar 02 2017 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Buy | M | 3.59 | 686,836 | 2,465,741 | 19,822,874 | 19.1 M to 19.8 M (+3.59 %) |
| Jan 04 2017 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | J | 0.00 | 2,242,664 | 0 | 0 | 2.2 M to 0 (-100.00 %) |
| May 10 2016 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Director | Option Exercise | M | 3.59 | 845,091 | 3,033,877 | 0 | |
| May 10 2016 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Director | Option Exercise | M | 3.59 | 8,349 | 29,973 | 0 | |
| May 10 2016 | NVCR | Novocure Ltd | DOYLE WILLIAM F | Director | Payment of Exercise | F | 12.59 | 240,976 | 3,033,888 | 21,378,702 | 21.6 M to 21.4 M (-1.11 %) |